Lisinopril-Induced Acute Pancreatitis

Thumma, Soumya; Errico, Kristen; Manchala, Venkata; Mattana, Joseph

doi:10.1097/mjt.0000000000000814

Cited by 6 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Medications have also been linked to acute pancreatitis. A case of lisinopril-induced pancreatitis has been reported in the past after starting on lisinopril two weeks before presentation [ 8 ]. It is unlikely that this could be the cause in our patient as she had been on the medication for many years before developing the episode.…”

Section: Discussionmentioning

confidence: 99%

Acute Pancreatitis: A Possible Side Effect of COVID-19 Vaccine

Parkash¹,

Sharko²,

Farooqi³

et al. 2021

Cureus

View full text Add to dashboard Cite

For the first time, the mRNA technology was utilized to produce a vaccine against COVID-19 after the unprecedented pandemic equally affected every part of the world. Pfizer-BioNTech (BNT162b2) mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was granted emergency use authorization (EUA) by Food and Drug Administration (FDA) in December 2020. EUA has been widely discussed in the medical literature and the general public. The safety of the BNT162b2 vaccine has been investigated in short-term trials with data available for three months. We present a case of a 96-year-old female with a past surgical history of cholecystectomy who presented with acute onset severe abdominal pain a few days after getting the first dose of Pfizer-BioNTech COVID-19 vaccine. She was diagnosed with acute pancreatitis with a lipase level of 4036 U/L. Extensive history and investigations were unable to find any etiology. The patient was conservatively managed and discharged home without any complications. There has been some data available in medical literature showing an association between acute pancreatitis and COVID-19 infection. Trial data of Pfizer COVID-19 also shows one case of acute pancreatitis in the treatment group. There have also been individual cases of unexplained acute pancreatitis shared by medical professionals on online forums. Our main goal to write this case is to make medical literature aware of possible emerging side effects of the COVID-19 vaccine, one of such side effects being self-resolving uncomplicated acute pancreatitis.

show abstract

Section: Discussionmentioning

confidence: 99%

Acute Pancreatitis: A Possible Side Effect of COVID-19 Vaccine

Parkash¹,

Sharko²,

Farooqi³

et al. 2021

Cureus

View full text Add to dashboard Cite

show abstract

“…Another rare cause for AP is drug induced and has been estimated to occur with an incidence of 0.1%-2% [3][4]. Although a link between many commonly prescribed drugs and AP has been discussed extensively in the literature, the exact mechanism of injury to the pancreas has not yet been completely elucidated but may be a result of pancreatic duct obstruction secondary to angioedema from increased bradykinins as well as autodigestion from prematurely activated pancreatic enzymes [5]. Management of drug-induced pancreatitis includes supportive care and immediate withdrawal of the offending medication.…”

Section: Discussionmentioning

confidence: 99%

Another Case of Lisinopril-Induced Acute Pancreatitis

Baum¹,

Walfish²,

Fenster³

et al. 2021

Cureus

View full text Add to dashboard Cite

Lisinopril as a cause for acute drug-induced pancreatitis is an emerging phenomenon that due to its generally low-risk profile often goes unnoticed. The true incidence of drug-induced pancreatitis is unknown, probably because of its nonrecognition among differential diagnosis. Only a handful of lisinopril-induced pancreatitis has been discussed in the literature, and little epidemiological evidence exists to establish true causality. Additionally, many of these reports have been met with skepticism claiming that it is difficult to isolate a true cause since many of these patients had comorbidities or were concomitantly taking other medications that may have contributed to the pancreatitis. Here, we report a case in which a generally otherwise healthy patient presented with acute drug-induced pancreatitis caused by an angiotensin-converting enzyme (ACE) inhibitor taken eight weeks prior to the onset of symptoms. The drug was immediately stopped, and the patient recovered well, with no complications.

show abstract

“…Albeit responsible for a small percentage of these costs, the contribution of DIP to the overall burden can be easily reduced. Since ACEi is the first-line treatment in patients with cardiovascular pathology, ACEi-associated AP is reported in the literature in the form of case reports [1,4] and case-control studies [5,8] . The length of time between ACEi administration and the development of AP resulting in pancreatic angioedema ranges from hours [9,10] to years [11] .…”

Section: Discussionmentioning

confidence: 99%

“…Thorough investigation of AP includes ruling out DIP among other causes. Although an association has been identified, ACEi-induced pancreatitis has rarely been described compared to reports implicating other drugs [1,4] . The relationship between dose modification and pancreatitis development has not been fully elucidated, representing a literature gap [5] .…”

Section: Introductionmentioning

confidence: 99%

“…

…”

mentioning

confidence: 98%

See 1 more Smart Citation

Angiotensin-Converting Enzyme (ACE) Inhibitors and Pancreatitis: A Potential Dose-dependent Relationship

Hussain

Deliwala

Ponnapalli

et al. 2020

European Journal of Case Reports in Internal Medicine

View full text Add to dashboard Cite

Acute pancreatitis (AP) remains one of the most common causes of emergency department visits in the USA. The literature supports an association between angiotensin-converting enzyme inhibitors (ACEi), mainly at steady-state doses, and AP. We present a case of recurrent AP and pseudocyst formation following multiple ACEi dose adjustments after a steady-state period lasting for over a decade. Previous reports have rarely described ACEi-induced pancreatitis and pseudocyst development. ACEi can cause significant ductal obstruction and fluid retention due to its angioedema effects. Consequently, it may trigger AP complicated by pseudocyst formation. Therefore, ACEi administration must be considered in the appropriate clinical context.

show abstract

Lisinopril-Induced Acute Pancreatitis

Cited by 6 publications

References 18 publications

Acute Pancreatitis: A Possible Side Effect of COVID-19 Vaccine

Acute Pancreatitis: A Possible Side Effect of COVID-19 Vaccine

Another Case of Lisinopril-Induced Acute Pancreatitis

Angiotensin-Converting Enzyme (ACE) Inhibitors and Pancreatitis: A Potential Dose-dependent Relationship

Contact Info

Product

Resources

About